Get the Stockscreener App
10.19
7.28%
-0.80
After Hours:
10.00
-0.19
-1.86%
Syndax Pharmaceuticals Inc stock is traded at $10.19, with a volume of 2.13M.
It is down -7.28% in the last 24 hours and down -8.69% over the past month.
Syndax Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on developing a pipeline of combination therapies in multiple cancer indications. Its product candidates include revumenib and axatilimab. It is developing revumenib, a selective menin-MLL inhibitor for KMT2A-rearranged (MLL-r) and NPM1-mutant acute leukemias, including ALL and AML. It is also developing axatilimab, a CSF-1R-blocking antibody for cGVHD and idiopathic pulmonary fibrosis. Entinostat is its oral, small molecule product candidate that has direct effects on both cancer cells and immune regulatory cells. The business activity of the group is functioned through the region of the United States.
See More
Previous Close:
$10.99
Open:
$11.03
24h Volume:
2.13M
Relative Volume:
1.03
Market Cap:
$915.54M
Revenue:
$139.71M
Net Income/Loss:
$-209.36M
P/E Ratio:
-3.4426
EPS:
-2.96
Net Cash Flow:
$-160.60M
1W Performance:
-4.23%
1M Performance:
-8.69%
6M Performance:
-38.73%
1Y Performance:
-51.41%
1-Day Range:
$10.10
$11.11
1-Week Range:
$9.665
$11.48
52-Week Range:
$9.66
$25.07
Syndax Pharmaceuticals Inc Stock (SNDX) Company Profile
Name
Syndax Pharmaceuticals Inc
Sector
Industry
Phone
781-419-1400
Address
730 THIRD AVENUE, NEW YORK, MA
Compare SNDX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
SNDX
Syndax Pharmaceuticals Inc
|
10.19 | 915.54M | 139.71M | -209.36M | -160.60M | -2.96 |
|
VRTX
Vertex Pharmaceuticals Inc
|
432.00 | 115.57B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
574.16 | 60.30B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ARGX
Argen X Se Adr
|
542.47 | 37.56B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
266.86 | 35.18B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ONC
Beigene Ltd Adr
|
224.73 | 26.10B | 3.81B | -644.79M | -669.77M | -6.24 |
Syndax Pharmaceuticals Inc Stock (SNDX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-24-24 | Initiated | UBS | Buy |
| Jun-28-24 | Initiated | Jefferies | Buy |
| Jan-31-24 | Downgrade | Scotiabank | Sector Outperform → Sector Perform |
| Dec-22-23 | Initiated | Mizuho | Buy |
| Oct-25-23 | Initiated | BofA Securities | Buy |
| Oct-11-23 | Initiated | Goldman | Buy |
| Jul-27-23 | Initiated | Scotiabank | Sector Outperform |
| Jul-11-23 | Initiated | Guggenheim | Buy |
| Apr-17-23 | Resumed | BTIG Research | Buy |
| Jan-31-23 | Initiated | Stifel | Buy |
| Jan-03-23 | Initiated | JP Morgan | Overweight |
| Jul-28-22 | Resumed | B. Riley Securities | Buy |
| Apr-11-22 | Initiated | H.C. Wainwright | Buy |
| Feb-15-22 | Initiated | Goldman | Buy |
| Jun-04-21 | Resumed | Robert W. Baird | Outperform |
| May-25-21 | Initiated | Citigroup | Buy |
| Feb-18-21 | Initiated | B. Riley Securities | Buy |
| Dec-03-20 | Initiated | Stifel | Buy |
| May-22-20 | Upgrade | Citigroup | Neutral → Buy |
| May-22-20 | Downgrade | H.C. Wainwright | Buy → Neutral |
| May-18-20 | Downgrade | Citigroup | Buy → Neutral |
| May-11-20 | Reiterated | H.C. Wainwright | Buy |
| Mar-04-20 | Initiated | Barclays | Overweight |
| Jan-13-20 | Reiterated | H.C. Wainwright | Buy |
| Mar-08-19 | Reiterated | H.C. Wainwright | Buy |
| Jan-04-19 | Initiated | Robert W. Baird | Outperform |
| Jan-05-18 | Initiated | B. Riley FBR, Inc. | Buy |
| Mar-16-17 | Initiated | FBR & Co. | Outperform |
| Mar-02-17 | Initiated | Instinet | Buy |
| Oct-07-16 | Initiated | Guggenheim | Buy |
| Mar-28-16 | Initiated | Citigroup | Buy |
| Mar-28-16 | Initiated | JMP Securities | Mkt Outperform |
| Mar-28-16 | Initiated | Morgan Stanley | Overweight |
View All
Syndax Pharmaceuticals Inc Stock (SNDX) Latest News
Voya Investment Management LLC Sells 45,352 Shares of Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) - MarketBeat
Syndax Pharmaceuticals Appoints Nicholas Botwood Chief Medical Officer - marketscreener.com
B. Riley Has Positive Outlook for SNDX Q2 Earnings - MarketBeat
SNDX Appoints New Head of Research and Development | SNDX Stock News - GuruFocus
Syndax Pharmaceuticals Appoints Dr. Nicholas Botwood as - GlobeNewswire
I Have a Prescription for These Two Biopharmas That Fell After Earnings - TheStreet Pro
Synlogic (SNDX) to Attend Meeting Hosted by B. Riley in New York - GuruFocus
Granahan Investment Management LLC Has $11.97 Million Stock Position in Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) - MarketBeat
Cubist Systematic Strategies LLC Invests $4.73 Million in Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) - MarketBeat
Crestline Management LP Has $9.43 Million Stake in Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) - MarketBeat
Syndax Pharmaceuticals' (SNDX) Buy Rating Reaffirmed at Guggenheim - MarketBeat
Scotiabank Issues Positive Forecast for Syndax Pharmaceuticals (NASDAQ:SNDX) Stock Price - MarketBeat
Syndax Pharmaceuticals (NASDAQ:SNDX) Releases Quarterly Earnings Results, Beats Expectations By $0.06 EPS - MarketBeat
Bayesian Capital Management LP Invests $370,000 in Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) - MarketBeat
Marshall Wace LLP Sells 977,280 Shares of Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) - MarketBeat
Algert Global LLC Buys 310,634 Shares of Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) - MarketBeat
Wall Street Analysts See a 219.98% Upside in Syndax (SNDX): Can the Stock Really Move This High? - Yahoo Finance
Syndax Announces Participation in May Investor Conferences - The Manila Times
Analysts Are Upgrading Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) After Its Latest Results - simplywall.st
Avidity Partners Management LP Cuts Holdings in Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) - MarketBeat
SNDX: Syndax Reveals Significant Phase 2 Trial Results for Revumenib | SNDX Stock News - GuruFocus
Analysts Set Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) PT at $36.20 - MarketBeat
Syndax Announces Publication of Pivotal Revumenib Data in - GlobeNewswire
Syndax Announces Publication of Pivotal Revumenib Data in Relapsed or Refractory mNPM1 Acute Myeloid Leukemia in the Journal Blood - Yahoo Finance
Syndax signals $4B total market opportunity with Revuforj expansion into frontline settings - MSN
Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Q1 2025 Earnings Call Transcript - Insider Monkey
Syndax Pharmaceuticals’ Optimistic Q1 2025 Earnings Call - TipRanks
SNDX: Scotiabank Raises Price Target on Syndax Pharmaceuticals | SNDX Stock News - GuruFocus
Syndax Pharmaceuticals (SNDX) Buy Rating Reiterated by Guggenhei - GuruFocus
Syndax Pharmaceuticals (SNDX) Buy Rating Reiterated by Guggenheim | SNDX Stock News - GuruFocus
Scotiabank raises Syndax stock target to $17 on strong sales By Investing.com - Investing.com Canada
Syndax (SNDX) Price Target Increased by BofA Following Promising Updates | SNDX Stock News - GuruFocus
BofA raises Syndax stock price target to $26 on strong Q1 update - Investing.com Canada
Syndax Pharmaceuticals Q1 Loss Widens - marketscreener.com
Syndax Pharmaceuticals Inc (SNDX) Q1 2025 Earnings Call Highlights: Strong Revenue Growth and ... - Yahoo Finance
Syndax Pharmaceuticals Inc (SNDX) Q1 2025 Earnings Call Highligh - GuruFocus
SNDX Reports Strong Revenue and Cash Position, Focuses on Growth - GuruFocus
Syndax Pharmaceuticals Reports Strong Q1 2025 Results - TipRanks
Earnings call transcript: Syndax Pharmaceuticals beats Q1 2025 EPS estimates - Investing.com Canada
Decoding Syndax Pharmaceuticals Inc (SNDX): A Strategic SWOT Ins - GuruFocus
Syndax Reports First Quarter 2025 Financial Results and Provides Business Update - GlobeNewswire
Syndax Pharmaceuticals, Inc. 2025 Q1ResultsEarnings Call Presentation (NASDAQ:SNDX) - Seeking Alpha
Syndax: Q1 Earnings Snapshot - MySA
Syndax Pharmaceuticals earnings beat by $0.26, revenue topped estimates - Investing.com Canada
Syndax Pharmaceuticals Q1 2025 Earnings: EPS Loss of $0.98 Beats Estimates, Revenue Surges to $20 Million - GuruFocus
Syndax Pharmaceuticals Inc Stock (SNDX) Financials Data
Revenue
Net Income
Cash Flow
EPS
3.01%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):